Repros Therapeutics — Investor Presentation (June 2013)
24 slides from Repros Therapeutics's investor presentation, Jun 7, 2013
Slide 1: Developing clinical stage small molecule therapeutics for hormonal and reproductive disorders
Developing clinical stage small molecule therapeutics to treat hormonal and reproductive system disorders
Slide 2: Repros Disclaimer
Repros Disclaimer Any statements made by the Company that are not historical facts contained in this release are forward - looking statements that involve risks and uncertainties, including the ability to raise additional needed capital on a timely basis in order for it to continue to fund developme
Slide 3: ANDROXAL Safety Review June 2013
ANDROXAL Safety Review 6 June 2013
Slide 4: Potential Safety Issues
Potential Safety Issues • Clomiphene – Cataracts – Increased estrogen (opposes testosterone increase) • Testosterone – Deep Vein Thrombosis (DVTs ) – Prostate Specific Antigen (PSA) Elevation – T level above normal – Decreased sperm count (infertility) – Gynecomastia • Hypogonadism - osteopenia
Slide 5: ANDROXAL Safety Review
ANDROXAL Safety Review 6 June 2013 ▪ Treatment Emergent Adverse Events (TEAEs) ▪ Discontinuation due to Adverse Events (DCAEs) ▪ Serious Adverse Events(SAEs) ▪ Testosterone ▪ Prostate Specific Antigen (PSA) ▪ Other Safety Issues Related to Testosterone Therapy
Slide 6: ANDROXAL Safety Review Topics and Studies
ANDROXAL Safety Review TOPICS STUDIES 003: Phase 3 301: Phase 3 300: long - term safety 303: bone density • Treatment Emergent Adverse Events (TEAEs) • Discontinuation due to Adverse Events (DCAEs) • Serious Adverse Events(SAEs) • Testosterone • Prostate Specific Antigen 300: long - term safety
Slide 7: Treatment Emergent Adverse Events
TREATMENT EMERGENT ADVERSE EVENTS Studies 301, 300, and 303 Study 301 Study 300 Study 303 Preferred Term 12.5 mg (%) 25 mg (%) PBO (%) 12.5 mg (%) 25 mg (%) 12.5 mg (%) 25 mg (%) PBO (%) N 90 22 37 259 240 94 69 104 Any Event 28 23 24 38 44 19 39 30 Upper respiratory infection 6 5 0 6 5 4 6 5 Headac
Slide 8: DC/AEs: Studies 301, 300, 303 and 003
DC/AEs : Studies 301, 300, 303 (green font indicates single subject) Study 301 Study 300 Study 303 Study 003 12.5 mg 25 mg PBO 12.5 mg 25 mg 12.5 mg 25 mg PBO 12.5 mg 25 mg Androgel PBO N = 90 22 37 259 240 94 69 104 47 50 48 49 Any DCAE (n = ) 0 1 1 5 1 1 2 0 1 1 5 1 PREFERR ED TERM Ocular discomf
Slide 9: Serious Adverse Events Reported in Studies 301, 300, and 303
Serious Adverse Events Reported in Studies 301, 300, and 303 ( green font indicates single subject) Study 301 Study 300 Study 303 12.5 mg 25 mg PBO 12.5 mg 25 mg 12.5 mg 25 mg PBO n 90 22 37 259 240 94 69 104 Any SAE (number of subjects) 0 0 0 2 5 0 2 Preferred Terms B radycardia K nee arthroplasty
Slide 10: Testosterone Levels
T ESTOSTERONE Study 300 at 6 - month point 0 200 400 600 800 1000 1200 Plasma Testosterone concentration TESTOSTERONE LEVELS ON LAST DAY OF DOSING (Study 300) 86% in NORMAL RANGE (300 - 1040) No excursions beyond n ormal range at 6 - months
Slide 11: PSA: baseline, end of treatment, follow-up
PSA: baseline, end of treatment, follow - up Study 300 (only subjects with data after Vis 5) 0 1 2 3 4 5 6 7 PSA ( ng /mL) BASELINE VIS 3, 4, 5, ET VIS 6,7,ET
Slide 12: PSA
PSA • PSA elevation is NOT an Adverse Drug Reaction • PSA elevation is an expected result of testosterone increase • PSA is not a cancer marker but a normal enzyme • Elevated PSA included in package insert for Axiron • Incidence and magnitude noted in Androxal studies is not alarming and has been re
Slide 13: Other Safety Issues Related to Testosterone Therapy
OTHER SAFETY ISSUES RELATED TO TESTOSTERONE THERAPY • Cataracts • Osteoporosis • Deep Vein Thrombosis
Slide 14: Safety Profile - Cataracts
Safety Profile - Cataracts • 1) – After 4 months, nuclear cataract in left eye disappeared, cortical cataract in right eye progressed – Described as age - related progression of senile cataract • 2) – Described as having cataract after 5 months of therapy, but all entries are “0”, same as baseline.
Slide 15: Safety Profile - DVT
Safety Profile - DVT • Deep Vein Thrombosis – One subject taking 12.5 mg Androxal developed a DVT after a 5 hour flight – Treated with anticoagulants to resolution • No other adverse events suggest incidence of DVT or other thrombotic events
Slide 16: Safety Profile – Bone Health
Safety Profile – Bone Health • Hypogonadism is associated with osteopenia • Study ZA - 303 captures bone mineral density assessments via DEXA for subjects over one year of Androxal exposure • Some subjects have completed DEXA analyses after 6 months of treatment – Early data suggests that Androxal s
Slide 17: Conclusions
CONCLUSIONS • Androxal is well tolerated • Findings are consistent with known pharmacology • No new safety issues
Slide 18: Clinical and Regulatory Team
Clinical and Regulatory Team • J.F. Wernicke, Ph.D., M.D., Chief Medical Officer – 30 years in clinical research – Ph.D. Biochemistry and MD Neurologist – Eli Lilly and Company, Clinical Research and Patient Safety • Jaye Thompson, Ph.D., Senior VP Clinical and Regulatory – Ph.D. Biostatistics – 25
Slide 19: Clinical and Regulatory Team
Clinical and Regulatory Team • Jennifer Nydell, Androxal Clinical Program Director – 17 years clinical research and development – 13 years Boehringer Ingelheim • Michele Rosner, Clinical Program Director – MS Biological Chemistry and Management – 16 years clinical development – 13 years with Pfizer
Slide 20: Androxal Study Status
Androxal Study Status Study Target Enrollment/Sites Duration Current Enrollment Top Line Results ZA 300 (Safety Study) 500 28 Sites 6 months Fully Enrolled 182 Completed Q4 2013 ZA-301 (Pivotal) 151 17 Sites 3 months Fully Enrolled Positive results on primary efficacy endpoints ZA-302 (Pivotal) 180
Slide 21: NDA Preparations
NDA Preparations • Building team – Contracting consultants and acquiring some additional staff • Evaluating and purchasing software and hardware for electronic NDA filing • Conducting audits of key clinical sites and vendors – No findings to date jeopardize data – Completed audit of central laborato
Slide 22: NDA Timeline
NDA Timeline Q4 2013 Q1 2014 Q2 2014 Q3 2014 NDA Phase I Studies ZA-302 ZA-300 Final Safety Data for ISS ISE Pre-NDA Meeting
Slide 23: Projected Cash Requirements Through H1 2015
Projected Cash Requirements Through H1 2015 (in millions) 2014 H1 2015 Total Androxal $7.5 $0 $7.5 Proellex $8.0 $6.0 $14.0 General Corporate $8.0 $4.5 $12.5 Total Cash Required Through Androxal Approval $34.0 Assumptions: Androxal - NDA filed in mid - 2014, expected approval mid - 2015; includes FD
Slide 24: Financial Summary
Financial Summary • Cash and equivalents (as of 4/1/13 - unaudited) $17.2 M • Cash runway: Q1 2014 • Current shares outstanding: 18.7 M shares – Warrants Outstanding – Series A – 877,137 (purchased in unit deal @ $2.45); Series B – 810,496 @ $2.49 exercise price.
Repros Therapeutics — Investor Presentation (June 2013) on 6ix